CRESCENT BIOPHARMA, INC. (CBIO)
$17.75-$0.01 (-0.06%) Today
Ryan Lynch - Officer
Jan Pinkas - Officer
Jonathan McNeill - OfficerCrescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
https://www.crescentbiopharma.comSEC filings for CBIO on EDGAR
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 1,379,347 | $20.00M |
| Open-market sale | 7 | 68,156 | $1.23M |
| Grant or award | 5 | 55,250 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
20 Form 4 filings on record, the earliest from Jun 13, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC - Director | Open-market purchase | Ordinary Shares | 853,450 | $14.50 | $12.38M | |
| Fairmount Funds Management LLC - Director | Open-market purchase | Pre-Funded Warrant (Right to Buy) | 525,897 | $14.50 | $7.62M | |
| Ryan Lynch - Officer | Open-market sale | Ordinary Shares | 465 | $17.99 | $8K | |
| Jan Pinkas - Officer | Open-market sale | Ordinary Shares | 1,288 | $17.99 | $23K | |
| Richard William Scalzo - Officer | Open-market sale | Ordinary Shares | 1,112 | $17.99 | $20K | |
| Barbara Harlin Bispham - Officer | Open-market sale | Ordinary Shares | 1,218 | $17.99 | $22K | |
| Ellie Eunkyung Im - Officer | Open-market sale | Ordinary Shares | 1,219 | $17.99 | $22K | |
| Jonathan McNeill - Officer | Open-market sale | Ordinary Shares | 20,549 | $17.99 | $370K | |
| Joshua T. Brumm - Officer | Open-market sale | Ordinary Shares | 42,305 | $17.99 | $761K | |
| Jonathan Violin - Director | Grant or award | Stock Option (Right to Buy) | 11,050 | $0.00 | - | |
| David Charles Lubner - Director | Grant or award | Stock Option (Right to Buy) | 11,050 | $0.00 | - | |
 Alexandra Balcom - Director | Grant or award | Stock Option (Right to Buy) | 11,050 | $0.00 | - | |
| Susan Moran - Director | Grant or award | Stock Option (Right to Buy) | 11,050 | $0.00 | - | |
| Fairmount Funds Management LLC - Director | Grant or award | Stock Option (Right to Buy) | 11,050 | $0.00 | - | |
| Jan Pinkas - Officer | Grant or award | Stock Option (Right to Buy) | 142,474 | $0.00 | - | |
| Jonathan Violin - Director | Grant or award | Stock Option (Right to Buy) | 9,023 | $0.00 | - | |
| David Charles Lubner - Director | Grant or award | Stock Option (Right to Buy) | 9,023 | $0.00 | - | |
| Susan Moran - Director | Grant or award | Stock Option (Right to Buy) | 9,023 | $0.00 | - | |
| Alexandra Balcom - Director | Grant or award | Stock Option (Right to Buy) | 9,023 | $0.00 | - | |
| Fairmount Funds Management LLC - Director | Grant or award | Stock Option (Right to Buy) | 9,023 | $0.00 | - | |
| BVF PARTNERS L P - 10% Owner | Other | Common Stock | 657,308 | - | - | |
| BVF PARTNERS L P - 10% Owner | Other | Common Stock | 556,617 | - | - | |
| BVF PARTNERS L P - 10% Owner | Other | Common Stock | 56,079 | - | - | |
| BVF PARTNERS L P - 10% Owner | Other | Pre-Funded Warrants to Purchase Common Stock | 304,098 | - | - | |
| BVF PARTNERS L P - 10% Owner | Other | Pre-Funded Warrants to Purchase Common Stock | 257,515 | - | - | |
| BVF PARTNERS L P - 10% Owner | Other | Pre-Funded Warrants to Purchase Common Stock | 25,944 | - | - |
CRESCENT BIOPHARMA, INC. (CBIO) had 13 insider filings in the last 90 days, with the most recent on 2026-07-20. The full record for CBIO runs to 20 Form 4 filings, the earliest from 2025-06-13. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
2 insider purchases of CBIO were filed in the last 90 days, totaling $20.00M.
7 insider sales of CBIO were filed in the last 90 days, totaling $1.23M.
This page tracks CBIO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CBIO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
